Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model

Staphylococcus aureus with intermediate glycopeptide susceptibility (glycopeptide-intermediate S. aureus [GISA]) has been isolated from patients with apparent therapy failures. We studied the killing activity of vancomycin over a range of simulated conventional doses (1 to 1.5 g every 12 h) against...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Aeschlimann, Jeffrey R., Allen, George P., Hershberger, Ellie, Rybak, Michael J.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2000
Assuntos:	Experimental Therapeutics
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101591/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036011/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.2991-2998.2000
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!